- Conditions
- Breast Cancer, Physical Inactivity
- Interventions
- Physical activity adoption, Self monitoring
- Behavioral
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes
- Interventions
- TExT-MED, FANS
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Nicotine Dependence
- Interventions
- Ad Libitum Use followed by Instructed Use of the Inspire Device, Instructed Use followed by Ad Libitum Use of the Inspire Device, Smart-T Smoking Cessation App with the Inspire Device Condition, Smart-T Smoking Cessation App Without the Inspire Device Condition, Nicotine replacement therapy (NRT), Inspire Device
- Device · Drug
- Lead sponsor
- University of Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pediatric Obesity
- Interventions
- Pro2 - 75% of participant's MIP, Pro2 - 15% of participant's MIP
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- CoronaVirus Induced Disease-2019 (COVID-19)
- Interventions
- Ibrutinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
- Conditions
- Intracranial Aneurysm
- Interventions
- Treatment of Intracranial Aneurysms
- Device
- Lead sponsor
- Medtronic Neurovascular Clinical Affairs
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 118 participants
- Timeline
- 2025 – 2033
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Marietta, Georgia • Carmel, Indiana + 5 more
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Diseases, Hypertension, Diabetes, Hyperlipidemia, Kidney Disease, Obesity, Smoking
- Interventions
- Inspire HER Intervention
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 30 Years to 79 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pneumonia
- Interventions
- INSPIRE CPOE Smart Prompt, Routine Care
- Other
- Lead sponsor
- Harvard Pilgrim Health Care
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44,780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 59
- States / cities
- Riverside, California • San Jose, California • Thousand Oaks, California + 51 more
- Conditions
- Autism Spectrum Disorder, Wearable Devices
- Interventions
- 14-Day Device Monitoring
- Device
- Lead sponsor
- Rady Pediatric Genomics & Systems Medicine Institute
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Cancer, Overweight and Obesity
- Interventions
- eHealth Intervention
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app
- Device
- Lead sponsor
- LifeScan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- Parkinson Disease
- Interventions
- Video and Activity Tracker
- Other
- Lead sponsor
- Jacob E. Simmering
- Other
- Eligibility
- 50 Years to 110 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Cancer Survivor, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Depression, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Psychosocial Effects of Cancer and Its Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
- Interventions
- internet-based intervention, questionnaire administration, psychosocial assessment and care, assessment of therapy complications, management of therapy complications, fatigue assessment and management, counseling intervention
- Other · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cancer, Melanoma (Skin Cancer), Immunotherapy
- Interventions
- Digital remote monitoring intervention, Usual Care
- Behavioral · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Covid19, ME/CFS, SARS COV2, Novel Coronavirus Infection, Neurocognitive Disorders, Cardiovascular Diseases
- Interventions
- Not listed
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,000 participants
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more
- Conditions
- Traumatic Thoracic Acute Spinal Cord Injury
- Interventions
- Neuro-Spinal Scaffold
- Device
- Lead sponsor
- InVivo Therapeutics
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more
- Conditions
- Obstructive Sleep Apnea, Obstructive Sleep Apnea of Adult
- Interventions
- No HGNS therapy (HGNS-off)
- Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dyspnea, Lung Cancer (Diagnosis)
- Interventions
- INSPIRE
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Capsaicin, Videofluoroscopic swallow study
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
- Interventions
- Biopsy of Bladder, Biospecimen Collection, Cisplatin, Computed Tomography, Cystoscopy, Durvalumab, Fluorouracil, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Mitomycin, Patient Observation, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 216
- States / cities
- Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 153 more
- Conditions
- Obstructive Sleep Apnea (OSA)
- Interventions
- Inspire® UAS System
- Device
- Lead sponsor
- Inspire Medical Systems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- Colorado Springs, Colorado • Bradenton, Florida • Chicago, Illinois + 2 more
- Conditions
- Cancer Survivors, Chronic Disease, Physical Activity, Cancer Survivorship, Physical Inactivity, Physical Activity in Adults
- Interventions
- mHealth/sFitRx, Fitness Tracker
- Other
- Lead sponsor
- The University of Tennessee, Knoxville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- SGT-003
- Genetic
- Lead sponsor
- Solid Biosciences Inc.
- Industry
- Eligibility
- 0 Years to 17 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Multiple Sclerosis, Secondary Progressive
- Interventions
- dimethyl fumarate, Placebo
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Long Beach, California • San Francisco, California • Tampa, Florida + 4 more